Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130390 · ClinicalTrials.gov registry record · Phase 2
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
A Phase 2 study, sponsored by Romark Laboratories L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00130390: Clinical Trial Phase 2 study, sponsored by Romark Laboratories L.C..
NCT00130390 is a Phase 2 study that was terminated before completion, run by Romark Laboratories L.C.. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130390, a Phase 2 study, was terminated before completion, sponsored by Romark Laboratories L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of nitazoxanide compared to a placebo in reducing the signs and symptoms of mild to moderate active Crohn's disease in adults.
Interventions
- OTHER Placebo
- DRUG Nitazoxanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Why NCT00130390 stopped before completion
NCT00130390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00130390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00130390 about?
NCT00130390 is a clinical study titled "Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease". The primary objective of this study is to evaluate the efficacy and safety of nitazoxanide compared to a placebo in reducing the signs and symptoms of mild to moderate active Crohn's disease in adults.
What is the current status of trial NCT00130390?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2005-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00130390?
The interventions under investigation include: Placebo (OTHER), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT00130390?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00130390's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia